Creation
Draft
Initial
Detailed
Accepted
Adoption
Idea Description
Supplementary Information
Detailed Submission Data
Innovation 'Elevator Pitch':
Coronary Artery Disease (CAD) is the leading cause of death world-wide. HeartFlow’s non-invasive technology, FFRct, has been found to accurately diagnose patients with suspected CAD, avoid unnecessary invasive procedures, and reduce healthcare costs
Overview of Innovation:
The diagnosis and care of patients with suspected coronary artery disease is significantly improved by the use of HeartFlow's FFRct analysis. Our process starts with data from a standard Coronary Computed Tomography Angiography (CCTA). High-quality (64 slice or greater) CT scanner images are sent to HeartFlow.

HeartFlow then creates a personalized, 3D model of each patient’s arteries. Where computational fluid dynamics are used to evaluate blood flow and assess the impact of blockages in the arteries. With this actionable information, clinicians can determine the right course of action for each patient.

While FFRct is still in an early stage of adoption, there are now over 150 publications on the technology. Clinical trials have validated both the diagnostic accuracy and clinical utility. Most recently NICE issued guidance on HeartFlow FFRct, stating "The technology is non-invasive and safe, and has a high level for diagnostic accuracy... may avoid the need for invasive coronary angiography... Based on current evidence using HeartFlow can lead to cost savings of £214 per patient."

CT data is securely (Anonymised CCTA data) and seamlessly sent via our “HeartFlow Connect” once installation is approved by the hospital trust. HeartFlow ensures that the scans and FFRct results and analysis models are acceptable to a sites radiologists / radiographers.

Whilst this is an emerging diagnostic its well positioned to become an integral part of standard patient care for those who are at risk of CAD. As this is a new technique HeartFlow provides training to radiologists, radiographers, cardiologists and support staff. We work closely with each site to provide support and training to help evaluate the technology and as they begin to incorporate FFRct into their clinical practice. [A high level overview of HeartFlow’s training support can be found in the Adoption guide published by NICE. (see attached)]

HeartFlow FFRct users are invited to educational seminars and we are working on establishing a UK users group to help sharing best practice around FFRct’s use.

HeartFlow has received CE mark approval for use in UK/Europe. CCTA image specifications for HeartFlow FFRct analysis; HeartFlow’s CCTA quality requirements are consistent with those of the Royal College of Radiology (RCR), British Society of Cardiovascular Imaging and the Society of Cardiovascular Computed Tomography (SCCT) performance of CCTA guidance document.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
Comments3
Similar Content

Comments

As a patient with all the meds no therapy this looks good  & this also goes to thoracic PAH /Apnea? & lipo-lymphoedema stage 2  This could assist in preventing Alzheimers [ MID  ] Which late mother had severely ?!This  is urgent  as already had MI [ cardiac arrest ] 13 years ago now 72 yrs , causing other conditions to worsen such as lipo-lymphoedema [ microvascular] Now Stage 2 with function & mobility extremely poor - disabling .If it stops driving am housebound .Late Mother MID hoisted everwhere function & cognition gone ??!
I was a payer in the US for 7 years and was introduced to HeartFlow during that period. The option to avoid invasive CTA is exciting indeed. This will lessen the workload an already over-burdened cath lab with a health economically viable number needed to treat. I think it's a great technology.
FFR-CT provides superior patient care and helps guide treatment strategies with a single, noninvasive study that is low risk and provides accurate information.  HeartFlow FFR-CT analysis has the potential to completely change the way we manage coronary artery disease.
 
5.7
3
Votes
-99999

Created by

Share and Follow